Published January 16, 2024 | Version v1
Publication Open

Nucleolar protein TAAP1/<i>C22orf46</i>confers pro-survival signaling in non-small cell lung cancer

  • 1. University Hospital Carl Gustav Carus
  • 2. National Center for Tumor Diseases
  • 3. University Hospital Heidelberg
  • 4. TU Dresden
  • 5. German Cancer Research Center
  • 6. Heidelberg University
  • 7. National Center for Genetic Engineering and Biotechnology

Description

Tumor cells subvert immune surveillance or lytic stress by harnessing inhibitory signals. Hence, bispecific antibodies have been developed to direct CTLs to the tumor site and foster immune-dependent cytotoxicity. Although applied with success, T cell–based immunotherapies are not universally effective partially because of the expression of pro-survival factors by tumor cells protecting them from apoptosis. Here, we report a CRISPR/Cas9 screen in human non-small cell lung cancer cells designed to identify genes that confer tumors with the ability to evade the cytotoxic effects of CD8 + T lymphocytes engaged by bispecific antibodies. We show that the gene C22orf46 facilitates pro-survival signals and that tumor cells devoid of C22orf46 expression exhibit increased susceptibility to T cell–induced apoptosis and stress by genotoxic agents. Although annotated as a non-coding gene, we demonstrate that C22orf46 encodes a nucleolar protein, hereafter referred to as "Tumor Apoptosis Associated Protein 1," up-regulated in lung cancer, which displays remote homologies to the BH domain containing Bcl-2 family of apoptosis regulators. Collectively, the findings establish TAAP1/ C22orf46 as a pro-survival oncogene with implications to therapy.

⚠️ This is an automatic machine translation with an accuracy of 90-95%

Translated Description (Arabic)

تقوم الخلايا السرطانية بتخريب المراقبة المناعية أو الإجهاد التحليلي عن طريق تسخير الإشارات المثبطة. وبالتالي، تم تطوير أجسام مضادة ثنائية النوعية لتوجيه CTLs إلى موقع الورم وتعزيز السمية الخلوية المعتمدة على المناعة. على الرغم من تطبيق العلاجات المناعية القائمة على الخلايا التائية بنجاح، إلا أنها ليست فعالة عالميًا جزئيًا بسبب التعبير عن العوامل المؤيدة للبقاء بواسطة الخلايا السرطانية التي تحميها من الاستماتة. هنا، نبلغ عن فحص CRISPR/Cas9 في خلايا سرطان الرئة البشرية ذات الخلايا غير الصغيرة المصممة لتحديد الجينات التي تمنح الأورام القدرة على التهرب من التأثيرات السامة للخلايا الليمفاوية CD8 + T التي تعمل بها أجسام مضادة ثنائية النوعية. نظهر أن جين C22orf46 يسهل الإشارات المؤيدة للبقاء وأن الخلايا السرطانية الخالية من تعبير C22orf46 تظهر قابلية متزايدة للاستماتة المستحثة بالخلايا التائية والإجهاد بواسطة العوامل السامة للجينات. على الرغم من شرحه على أنه جين غير مشفر، إلا أننا نثبت أن C22orf46 يشفر بروتينًا نوويًا، يشار إليه فيما يلي باسم "البروتين المرتبط بالموت المبرمج للورم 1"، والذي يتم تنظيمه في سرطان الرئة، والذي يعرض التماثلات البعيدة لمجال BH الذي يحتوي على عائلة Bcl -2 من منظمات الموت المبرمج. بشكل جماعي، تؤسس النتائج TAAP1/ C22orf46 كجين ورمي مؤيد للبقاء مع آثار على العلاج.

Translated Description (English)

Tumor cells subvert immune surveillance or lytic stress by harnessing inhibitory signals. Hence, bispecific antibodies have been developed to direct CTLs to the tumor site and foster immune-dependent cytotoxicity. Although applied with success, T cell–based immunotherapies are not universally effective partially because of the expression of pro-survival factors by tumor cells protecting them from apoptosis. Here, we report a CRISPR/Cas9 screen in human non-small cell lung cancer cells designed to identify genes that confer tumors with the ability to evade the cytotoxic effects of CD8 + T lymphocytes engaged by bispecific antibodies. We show that the C22orf46 gene facilitates pro-survival signals and that tumor cells devoid of C22orf46 expression exhibit increased susceptibility to T cell–induced apoptosis and stress by genotoxic agents. Although annotated as a non-coding gene, we demonstrate that C22orf46 encodes a nucleolar protein, hereafter referred to as "Tumor Apoptosis Associated Protein 1," up-regulated in lung cancer, which displays remote homologies to the BH domain containing Bcl-2 family of apoptosis regulators. Collectively, the findings establish TAAP1/ C22orf46 as a pro-survival oncogene with implications to therapy.

Translated Description (French)

Tumor cells subvert immune surveillance or lytic stress by harnessing inhibitory signaux. Hence, bispecific antibodies have been developed to direct CTLs to the tumor site and foster immune-dependent cytotoxicity. Although applied with success, T cell–based immunotherapies are not universally effective partially because of the expression of pro-survival factors by tumor cells protecting them from apoptosis. Here, we report a CRISPR/Cas9 screen in human non-small cell lung cancer cells designed to identify genes that confer tumors with the ability to evade the cytotoxic effects of CD8 + T lymphocytes engaged by bispecific antibodies. We show that the gene C22orf46 facilites pro-survival signals and that tumor cells devoid of C22orf46 expression exhibit increased susceptibility to T cell–induced apoptosis and stress by genotoxic agents. Although annotated as a non-coding gene, we demonstrate that C22orf46 encodes a nucleolar protein, hereafter referred to as « Tumor Apoptosis Associated Protein 1, » up-regulated in lung cancer, which displays remote homologies to the BH domain containing Bcl-2 family of apoptosis regulators. Collectively, the findings establish TAAP1/ C22orf46 as a pro-survival oncogene with implications to therapy.

Translated Description (Spanish)

Tumor cells subvert immune surveillance or lytic stress by harnessing inhibitory signals. Hence, bispecific antibodies have been developed to direct CTLs to the tumor site and foster immune-dependent cytotoxicity. Although applied with success, T cell–based immunotherapies are not universally effective partially because of the expression of pro-survival factors by tumor cells protecting them from apoptosis. Here, we report a CRISPR/Cas9 screen in human non-small cell lung cancer cells designed to identify genes that confer tumors with the ability to evade the cytotoxic effects of CD8 + T lymphocytes engaged by bispecific antibodies. We show that the gene C22orf46 facilitates pro-survival signals and that tumor cells devoid of C22orf46 expression exhibit increased susceptibility to T cell–induced apoptosis and stress by genotoxic agents. Although anotated as a non-coding gene, we demonstrate that C22orf46 encodes a nucleolar protein, hereafter referred to as "Tumor Apoptosis Associated Protein 1," up-regulated in lung cancer, which displays remote homologies to the BH domain containing Bcl-2 family of apoptosis regulators. Collectively, the findings establish TAAP1/ C22orf46 as a pro-survival oncogene with implications to therapy.

Files

e202302257.full.pdf.pdf

Files (5.7 MB)

⚠️ Please wait a few minutes before your translated files are ready ⚠️ Note: Some files might be protected thus translations might not work.
Name Size Download all
md5:72c8a656c04e8de7753863035693efcf
5.7 MB
Preview Download

Additional details

Additional titles

Translated title (Arabic)
البروتين النووي TAAP1/C22orf46<i> يعطي</i> إشارات مؤيدة للبقاء في سرطان الرئة ذو الخلايا غير الصغيرة
Translated title (English)
Nucleolar protein TAAP1/<i>C22orf46</i>confers pro-survival signaling in non-small cell lung cancer
Translated title (French)
Protéine nucléolaire TAAP1/<i>C22orf46</i>confers pro-survival signaling in non-small cell lung cancer
Translated title (Spanish)
Proteína nuclear TAAP1/<i>C22orf46</i>confers pro-survival signaling in non-small cell lung cancer

Identifiers

Other
https://openalex.org/W4390904552
DOI
10.26508/lsa.202302257

GreSIS Basics Section

Is Global South Knowledge
Yes
Country
Thailand

References

  • https://openalex.org/W1602931439
  • https://openalex.org/W1607777232
  • https://openalex.org/W1803102843
  • https://openalex.org/W1825962579
  • https://openalex.org/W1829569078
  • https://openalex.org/W1970108205
  • https://openalex.org/W1972761833
  • https://openalex.org/W1978542424
  • https://openalex.org/W1981188497
  • https://openalex.org/W1981593008
  • https://openalex.org/W1985255881
  • https://openalex.org/W1987134040
  • https://openalex.org/W1989410548
  • https://openalex.org/W1994993231
  • https://openalex.org/W2013658872
  • https://openalex.org/W2019733630
  • https://openalex.org/W2032361307
  • https://openalex.org/W2041086028
  • https://openalex.org/W2045031211
  • https://openalex.org/W2054841768
  • https://openalex.org/W2060617511
  • https://openalex.org/W2062060771
  • https://openalex.org/W2062993008
  • https://openalex.org/W2068427957
  • https://openalex.org/W2071531866
  • https://openalex.org/W2076591428
  • https://openalex.org/W2085419794
  • https://openalex.org/W2091483784
  • https://openalex.org/W2099806709
  • https://openalex.org/W2101683327
  • https://openalex.org/W2105330984
  • https://openalex.org/W2107620713
  • https://openalex.org/W2109956888
  • https://openalex.org/W2114872225
  • https://openalex.org/W2123364539
  • https://openalex.org/W2127132803
  • https://openalex.org/W2128791472
  • https://openalex.org/W2130410032
  • https://openalex.org/W2132165198
  • https://openalex.org/W2152636515
  • https://openalex.org/W2160716633
  • https://openalex.org/W2162560719
  • https://openalex.org/W2167279371
  • https://openalex.org/W2170243414
  • https://openalex.org/W2179438025
  • https://openalex.org/W2214074259
  • https://openalex.org/W2252568502
  • https://openalex.org/W2252711380
  • https://openalex.org/W2318671945
  • https://openalex.org/W2323326409
  • https://openalex.org/W2329974159
  • https://openalex.org/W2334685455
  • https://openalex.org/W2336890914
  • https://openalex.org/W2342536142
  • https://openalex.org/W2400514548
  • https://openalex.org/W2620721366
  • https://openalex.org/W2734530451
  • https://openalex.org/W2744743363
  • https://openalex.org/W2759226391
  • https://openalex.org/W2770893462
  • https://openalex.org/W2789620675
  • https://openalex.org/W2791483720
  • https://openalex.org/W2792200327
  • https://openalex.org/W2792441487
  • https://openalex.org/W2800128349
  • https://openalex.org/W2801298049
  • https://openalex.org/W2889646458
  • https://openalex.org/W2893126573
  • https://openalex.org/W2900245702
  • https://openalex.org/W2922124059
  • https://openalex.org/W2988945649
  • https://openalex.org/W2990427812
  • https://openalex.org/W2999636349
  • https://openalex.org/W3024392979
  • https://openalex.org/W3028304854
  • https://openalex.org/W3086730128
  • https://openalex.org/W3093027885
  • https://openalex.org/W3096016553
  • https://openalex.org/W3133670891
  • https://openalex.org/W3135190368
  • https://openalex.org/W3135882325
  • https://openalex.org/W3163595068
  • https://openalex.org/W3165851349
  • https://openalex.org/W3177828909
  • https://openalex.org/W3179433157
  • https://openalex.org/W3203459683
  • https://openalex.org/W4205247356
  • https://openalex.org/W4207067088
  • https://openalex.org/W4220724561
  • https://openalex.org/W4221131693
  • https://openalex.org/W4225529913
  • https://openalex.org/W4292291457
  • https://openalex.org/W4297348437
  • https://openalex.org/W4307425304
  • https://openalex.org/W4308365352
  • https://openalex.org/W4309506674
  • https://openalex.org/W4313472507
  • https://openalex.org/W4327850299
  • https://openalex.org/W4365479582
  • https://openalex.org/W4377940638